Discover and read the best of Twitter Threads about #sitc22
Most recents (1)
1/ “Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.” $PVCT thoughts: there’s no free lunch. A THREAD.
2/ 20Mar23: Endpoints: “BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal.” endpts.com/biontech-to-pa….
3/ The CTLA-4 asset BioNTech acquired is ONC-392. See here from #SITC21: jitc.bmj.com/content/jitc/9….
